Last reviewed · How we verify
Liraglutide injection
Liraglutide injection is a GLP-1 receptor agonist Small molecule drug developed by Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca. It is currently FDA-approved for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients. Also known as: Victoza, victoza, Nuo he li, Placebo.
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby reducing blood glucose and promoting weight loss.
Liraglutide is a glucagon-like peptide 1 receptor agonist used to treat various conditions, including Type 1 Diabetes Mellitus, Autoimmune Diabetes, Obesity, Type 2 Diabetes Treated With Insulin, and Adolescent Obesity. It works by activating the glucagon-like peptide 1 receptor, a protein involved in glucose regulation.
At a glance
| Generic name | Liraglutide injection |
|---|---|
| Also known as | Victoza, victoza, Nuo he li, Placebo |
| Sponsor | Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes; Obesity |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural incretin hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, inhibits glucagon release when blood glucose is elevated, and delays gastric emptying to reduce postprandial glucose spikes. These combined effects lower blood glucose levels and reduce appetite, leading to weight loss.
Approved indications
- Type 2 diabetes mellitus
- Chronic weight management in obese or overweight patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia (when combined with insulin or sulfonylureas)
Key clinical trials
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (PHASE2)
- Effects of GH and Lirglutide on AgRP (PHASE4)
- Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery (PHASE4)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis (PHASE2)
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide injection CI brief — competitive landscape report
- Liraglutide injection updates RSS · CI watch RSS
- Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca portfolio CI
Frequently asked questions about Liraglutide injection
What is Liraglutide injection?
How does Liraglutide injection work?
What is Liraglutide injection used for?
Who makes Liraglutide injection?
Is Liraglutide injection also known as anything else?
What drug class is Liraglutide injection in?
What development phase is Liraglutide injection in?
What are the side effects of Liraglutide injection?
What does Liraglutide injection target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca — full pipeline
- Therapeutic area: All drugs in Diabetes; Obesity
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Chronic weight management in obese or overweight patients
- Also known as: Victoza, victoza, Nuo he li, Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing